2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Provides Regulatory Update on Tabelecleucel
Provides a Business Update
Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Fourth Amendment to Commercialization Agreement with Pierre Fabre
Announces Third Quarter Financial Results and Operational Progress
Costs of Shutting Down or Selling Parts of the Business
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Definitive Revised Proxy Statement
Correspondence